 If you are still eligible to take part in this study, you will be randomly assigned as in the roll of the dice to one of 3 treatment groups. Participants in the first group will be given Ondansetron as an intravenous IV--through a needle in your vein continuous infusion, from 30 minutes before your chemotherapy treatment until 12 hours after chemotherapy ends. This is considered the standard of care. 